Millions of Americans take monthly injections to keep migraines at bay. Now researchers say those same drugs may be protecting them from glaucoma, a leading cause of blindness.
A large study, published in Neurology, found that patients taking calcitonin gene-related peptide (CGRP) inhibitors, a newer class of migraine prevention drugs, were 25 percent less likely to develop glaucoma than those on older treatments, raising hope that these medications offer unexpected benefits for eye health.
